Business

Know the Business

Lee & Man Chemical is a small but unusually profitable Chinese chlor-alkali producer that earns commodity-chemical margins closer to a specialty formulator. The reason is not a moat in the normal sense — it is a tight, vertically-integrated three-plant footprint in the PRC, cheap captive power, and a hardwired offtake relationship with sister company Lee & Man Paper (2314.HK) that soaks up caustic soda and bleach at industrial scale. The market tends to price 0746 as a pure commodity cyclical at 6–7x earnings with a 7% dividend yield; what it underestimates is how much of the margin stack is a structural captive-demand + low-cost-electrolysis story, and what it overestimates is how much of the recent profit rebound is durable as opposed to a raw-material-price windfall.

How This Business Actually Works

Lee & Man Chemical sells salt-and-electricity: it runs chlor-alkali electrolysis at three PRC sites (Jiangsu/Changshu, Jiangxi/Jiujiang, Zhuhai/Guangdong) that crack brine into caustic soda, chlorine and hydrogen, then monetises every output stream. One input, six product families, one customer base dominated by Chinese pulp-paper, textile, alumina, PTA, food and water-treatment buyers. Revenue in FY2024 breaks out as HK$1.6B caustic soda (41% of chemical sales), HK$921M chloromethanes, HK$352M hydrogen peroxide, HK$317M fluorochemicals (PTFE, FEP, HFP), HK$410M polymers and a small residual of lithium-battery electrolyte additives. Annual physical volume is ~590k tonnes dry-basis caustic, ~400k tonnes chloromethanes, ~410k tonnes hydrogen peroxide, ~9k tonnes PTFE.

The economic engine has three moving parts most people miss. First, caustic and chlorine are joint products of the same electrolysis cell — you cannot make one without making the other. So profitability is set not by caustic prices alone but by the ECU (electrochemical unit: 1 tonne caustic + 0.89 tonne chlorine). When caustic is weak, chlorine usually isn't, and vice versa — the derivatives business (chloromethanes, PVC, H2O2) is there to convert cheap chlorine into something sellable. Second, electricity is 35–45% of cash cost; Jiangxi and Jiangsu run captive coal-fired power plants with thermal-integrated steam recovery, which is why unit energy consumption (306 kgce/t of caustic at Jiangsu, 297 at Jiangxi) sits well under the national 330 kgce/t average. Every RMB50/t of coal move drops straight to gross margin. Third, a material slice of caustic soda and sodium hypochlorite goes directly to Lee & Man Paper — the sister company — as captive offtake. This is disclosed as related-party revenue rather than marketed at spot, and it is both a floor on utilisation and a negotiating anchor that peers without a sister buyer do not get.

Incremental profit is driven by ECU margin × volume, and because the asset base is already built, the operating leverage is brutal in both directions: gross margin moved from 26.2% in FY2023 to 34.5% in FY2025 with volumes roughly flat.

The Playing Field

Set against real chlor-alkali and vinyl peers, Lee & Man Chemical is a financial outlier — tiny in revenue, the best in margins and the cleanest balance sheet in the cohort. Most global commodity chemical peers (Olin, Westlake, Dow, Formosa Plastics) posted GAAP losses in FY2025 after the 2021–22 super-cycle unwound; 0746 still made HK$558M of net profit on a 34.5% gross margin. That gap deserves an explanation, not a nod.

The peer set reveals three things. First, scale does not confer margin advantage in chlor-alkali — Dow is 80x larger by revenue but earns negative margins, while 0746 earns mid-teens net. The returns curve is U-shaped: either you are very large with global logistics (Olin), or you are small-to-mid with low cost power and local demand density. 0746 sits in the second camp. Second, the only peer with comparable margin quality is Tosoh, which is not a coincidence — Tosoh also pairs chlor-alkali with a high-value captive downstream (electronic materials, silica, HPLC). This is the template. Third, 0746's balance sheet is the cleanest in the cohort: net debt / equity of 0.06 vs 0.30–1.45 for the Western peers. That is the luxury that lets it stay full-load through downturns without ever being forced to sell an asset or cut a dividend.

Is This Business Cyclical?

Yes, intensely so — but the cycle hits price and margin far more than volume, because volumes are anchored by captive offtake and fixed PRC plant utilisation. Look at what happened from FY2017 to FY2025: revenue swung from HK$3.0B (FY2017) to HK$5.9B (FY2022) and back to HK$3.8B (FY2025), while reported volumes barely moved. The volatility is almost entirely ECU price × raw material spread, not demand.

The margin series tells the story. The 2017–2018 caustic supercycle pushed gross margin to 47% (Chinese environmental shutdowns took competing capacity offline). The 2020 COVID demand shock knocked it to 36.5% despite volume resilience. 2021 rebounded on tight China caustic-chlorine spreads (45%). 2023 was the trough — caustic ASP fell ~26% YoY (RMB950/t) and chloromethane ASP fell 31–50% while coal cost eased more slowly, compressing gross margin to 26.2%. FY2024–25 is a mid-cycle grind-back to 34.5%, driven entirely by lower raw-material and energy costs; chemical ASPs themselves are not rising.

Three things about this cycle to internalise. Working capital actually moves the wrong way in a downturn: inventory write-downs accelerate (FY2023: HK$7M; FY2024: HK$6M plus HK$1M on property) and debtor days drifted from 22 in 2023 to 29 in 2024 as downstream customers stretched payment. Capex stayed stubbornly high — HK$614M in trough-FY2023 vs HK$524M in boom-FY2018, because the Jiangxi fluoropolymer, Changshu VC and Zhuhai FEC lines were mid-construction. That meant FCF collapsed to HK$142M in FY2023 vs nearly HK$1B the year before, and the dividend was cut from HK14c+HK17c in FY2022 to HK5c+HK14c in FY2023 — a 44% reduction. The recovery is incomplete: FY2025 gross margin of 34.5% is still 10+ points below the 2017–18 and 2021 peaks. Anyone modelling a return to 45% margins is implicitly betting on another China supply-side shock.

The Metrics That Actually Matter

Forget revenue growth and forget accrual EPS. Five numbers, in this order, explain whether value is being created.

The critical insight from the scorecard: this company's economic value is being generated by the 4–5 years that margins are elevated, not the 2–3 trough years. Over FY2018–2025, cumulative FCF was HK$3.9B and cumulative dividends HK$2.5B — a 64% through-cycle payout. The balance sheet absorbed the rest through capex (HK$5.2B) with debt net-flat. This is the actual engine — high-margin windows funding capex plus dividends without leverage, and trough years managed by cutting the payout rather than the plant. Anyone tracking only quarterly EPS or the dividend yield on screen misses this entirely.

What I'd Tell a Young Analyst

Three things. First, stop thinking of this as a specialty chemical company. The fluoropolymer and Li-ion additive revenue lines are optionality, not the business — 80%+ of revenue and virtually all the profit comes from caustic soda and chloromethanes. You value the company by pricing ECU margins through-cycle (call it HK$1.0–1.2B of normalised EBITDA) and cross-checking against replacement cost of three PRC electrolysis sites with captive power. Do not pay a specialty-chemical multiple.

Second, the captive offtake is the single biggest unverifiable variable. The annual report confirms related-party sales to Lee & Man Paper but does not break them out in a form that lets you see the transfer price. If Paper is paying market, the relationship is a volume floor only; if Paper is paying below-market, 0746 is cross-subsidising the sister and reported margins are understated relative to what an independent sale would generate. Either way, if Paper ever sources elsewhere or a regulator forces arm's-length pricing, the economics change. Watch 2314's caustic-soda purchasing disclosures.

Third, the thesis-killers are specific and watchable. Coal costs and PRC grid tariffs drive 35–45% of cash cost — any structural rise in Jiangxi/Jiangsu industrial power tariffs should immediately reset the earnings power. The new Jiangxi high-end fluoropolymer line is a capital-cost sink that does not yet earn anything; if its IRR disappoints, FY2026–27 ROIC will show it through falling asset turnover. And the dividend — which the street reads as a yield floor — was cut 44% in FY2023 and can be again; do not treat it as a bond coupon. The thing that would genuinely change the thesis in the other direction is Chinese chlor-alkali supply-side consolidation (tighter emissions rules forcing small operators out, like 2017–18) which would lift ECU margins back to 45%+ and, against a zero-leverage balance sheet, generate a full-cycle re-rate.

If you only track five things: caustic soda ASP in RMB/t, chloromethane ASP, China thermal-coal QHD price, Lee & Man Paper's caustic consumption, and 0746's half-year gross margin. Everything else is downstream of those five.